TL;DR Science: Sotrovimab, and other monoclonal antibody COVID-19 treatments

By Thomas P
February 02, 2022 · 2 minute read



Biological Engineering

Since the start of the worldwide COVID-19 pandemic, many treatments for the disease (and virus - SARS-CoV-2) have since emerged. But few have been able to withstand the storm of the variants that have followed the initial iteration of the virus: Alpha, Beta, Delta, Omicron. For example, the treatment produced by the company Regeneron has been largely discontinued since it is impotent against the Omicron variant, while the treatment Sotrovimab (discussed in this article) has not. Today, we will be discussing why. 

About such treatments

Firstly, let us start with giving a name to these treatments which use artificial antibodies to fight the disease: they are called monoclonal antibodies (abbreviated mAbs). 

For our readers that currently do not know what antibodies are, they are proteins used by our bodies to neutralize viruses. Artificially made antibodies such as mAbs would be used in the case primarily for facilitating the launch of an immune response primarily in people that are immunocompromised. 

mAbs are known to reduce the severity of COVID-19, even in patients who lack the normal immune response. For example, they have been known to prevent admissions to the ICU in the cases of patients in which this otherwise might have been the case. However, mAbs are not effective in patients whose case has already progressed to be extremely severe. As a result, the FDA only allows hospitals to administer these treatments as a preventative measure in patients whose cases have only progressed to become mild to moderately severe.

Manufacturing mAbs

Duke University explains that there are two processes that take place: an upstream process which includes the extraction of the “crude protein drug [monoclonal antibody] via cell culture in a bioreactor” and a downstream process which involves sterilization and purification.

Eligibility requirements

The FDA has stated that in order to be eligible for the treatment one must have mild to moderate COVID, but should also fulfill one of several criterions (exclusively, the below are merely examples not all are listed):  

A person should be: 

  • 65 years old or older
  • Obese or overweight
  • Pregnant 
  • Diabetic
  • Immunosuppressed or immunocompromised

Or have: 

  • Cardiovascular disease or hypertension
  • Chronic lung diseases (e.g. asthma)
  • Sickle cell disease
  • Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes)
  • Having a medical-related technological dependence (perhaps as a result of a surgery - should not be related to COVID illness. 


Availability of Sotrovimab 

mAbs are quite scarce, and as such can only be given to people who may have serious illness without the treatment. This does not preclude Sotrovimab, for example the president of the Henry Ford Health System in Detroit stated in December 2021 to The New York Times that they anticipated only a meager supply of the medicine; likewise an article in The Orlando Sentinel stated recently (January 2022) that the treatment is still in short supply. 

TL;DR: Sotrovimab is a type of monoclonal antibody that is effective against the Omicron variant.


Did you enjoy this article?

About The Author

Thomas is a student at Eastside High School.

More on this topic...

TL;DR Science: Artificial Intelligence in Healthcare

Artificial Intelligence (AI) is revolutionizing the field of healthcare, bringing forth a new era of personalized medicine, improved diagnostics, and enhanced patient care. With its ability to analyze vast amounts of data, identify patterns, and make intelligent predictions, AI is transforming the way healthcare professionals diagnose diseases, develop treatment plans, and manage patient outcomes. Find out more in this week's article!

TLDR: Exploring the Frontier of Science: Bioinformatics and Genomic Data Analysis

In today's ever-evolving world of science, one field stands at the crossroads of biology and computer science, promising exciting discoveries and breakthroughs. Bioinformatics and genomic data analysis are captivating domains that offer an intriguing glimpse into the fusion of technology and life sciences. Check out the article this week to learn more!

TL;DR Science - Vitamins and Minerals

Regardless of our age, we’ve always been told to eat balanced.  Fruits and vegetables form a large part of that ideal diet.  However, we don’t always think about why that is; sure, they’re healthy, but what makes them so important to our eating habits?  What about proteins – what makes lean meats or lentils the central focus of many of our plates?  The answer is pretty simple: all these foods are packed with nutrients. Read this week's article on vitamins and minerals!

TL;DR Science: Allergies

Have you ever wondered why some of us are unaffected by springtime pollen while others find themselves sneezing?  Or why not everyone can enjoy a good peanut butter and jelly sandwich without having a reaction?  What really causes these allergies, and why do they vary among different people? Find out more in this week's article!

TL;DR Science: The Future of Remote Patient Monitoring (RPM):

Remote patient monitoring is an innovative approach in healthcare that utilizes advancements in information technology to gather patient data outside of the conventional health care environment. It is also referred to as remote patient management, remote health monitoring, or remote physiologic monitoring. Check out this week's article to learn more about its software and benefits!